Vol 7, Supplement 6 (July 30, 2018): Translational Cancer Research (Prostate Cancer: Current Understanding and Future Directions)

Review Article

Hypofractionation in prostate cancer radiotherapy

David J. Brenner, Eric J. Hall

PDF Pages: S632-S639 Full Text (6088) COI Form Open Access

Genetic signatures on prostate biopsy: clinical implications

Justin T. Matulay, Sven Wenske

PDF Pages: S640-S650 Full Text (2895) COI Form Open Access

Prostate cancer: unmet clinical needs and RAD9 as a candidate biomarker for patient management

Howard B. Lieberman, Alex J. Rai, Richard A. Friedman, Kevin M. Hopkins, Constantinos G. Broustas

PDF Pages: S651-S661 Full Text (5822) COI Form Open Access

Neoadjuvant therapies for surgical management of high risk, localized prostate cancer

Nina Mikkilineni, Elias S. Hyams

PDF Pages: S662-S675 Full Text (4678) COI Form Open Access

Prostate-specific membrane antigen in prostate cancer imaging and treatment

Emerson Lim

PDF Pages: S676-S689 Full Text (5331) COI Form Open Access

2^nd generation anti-androgens and radiotherapy for localized prostate cancer

Tomer Charas, Sean McBride

PDF Pages: S690-S694 Full Text (2308) COI Form Open Access

Androgen deprivation therapy and radiation therapy for prostate cancer: the mechanism underlying therapeutic synergy

Catherine S. Spina

PDF Pages: S695-S703 Full Text (10679) COI Form Open Access

Editorial

Genetic signatures on radical prostatectomy specimens: clinical implications

Christopher B. Anderson, G. Joel DeCastro

PDF Pages: S704-S710 Full Text (1594) COI Form Open Access

Disclosure:

The supplement “Prostate Cancer: Current Understanding and Future Directions” was commissioned by the editorial office, Translational Cancer Research without any sponsorship or funding. Israel Deutsch, Charles G Drake and James McKiernan served as the unpaid Guest Editors for the supplement.